Considering the intratumoral heterogeneity of HER2+ BC and the differences between HR+/HER2+ and HR-/HER2+ subtypes, there is an opportunity to investigate other targeted combinations in randomized clinical trials specifically aimed at HR+/HER2+ BC patients, exploring the potential for combination blockade. The gene discussed is ERBB2; the disease is breast cancer.